Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan
about
MicroRNAs as growth regulators, their function and biomarker status in colorectal cancerLet-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysisSNPing cancer in the bud: microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancerA KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancerMiRNAs and miRNA Polymorphisms Modify Drug ResponseSerum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapySNPs in microRNA binding sites as prognostic and predictive cancer biomarkersColorectal Cancer: From the Genetic Model to Posttranscriptional Regulation by Noncoding RNAs.Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).Galectin-3 mediates cross-talk between K-Ras and Let-7c tumor suppressor microRNAThe involvement of Kras gene 3'-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis.A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.MicroRNA signatures differentiate melanoma subtypes.Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximabLin28 induces epithelial-to-mesenchymal transition and stemness via downregulation of let-7a in breast cancer cells.The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer.RETRACTED: Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells.MicroRNAs and Gastroenterological Cancers.A variant in 3'-untranslated region of KRAS compromises its interaction with hsa-let-7g and contributes to the development of lung cancer in patients with COPDDown-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancerPrognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease.The role of microRNAs in colorectal cancer.Prognostic significance of microRNA gene polymorphisms in patients with surgically resected colorectal cancer.A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysisPrognostic and predictive roles of KRAS mutation in colorectal cancer.MicroRNA binding site polymorphisms as biomarkers of cancer risk.Discovery and functional assessment of gene variants in the vascular endothelial growth factor pathwayExtensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases.MicroRNA-566 activates EGFR signaling and its inhibition sensitizes glioblastoma cells to nimotuzumab.MicroRNA binding-site polymorphisms as potential biomarkers of cancer risk.Regulation of microRNA expression and function by nuclear receptor signaling.Pharmacogenomics and metastatic colorectal cancer: current knowledge and perspectives.Selecting the best targeted agent in first-line treatment of unresectable liver metastases from colorectal cancer: does the bench have the answers?miRNA pharmacogenomics: the new frontier for personalized medicine in cancer?microRNAs in colon cancer: a roadmap for discovery.Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistanceTherapeutic resistance in cancer: microRNA regulation of EGFR signaling networks.Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer.
P2860
Q26775610-F652ECF5-5626-4AF8-B606-58A950B41678Q26827474-D1BBFB61-E1F6-492E-9234-46F8EE111CFEQ26829794-73E0B01C-E2DA-438B-B797-2B485AEE9E2FQ27851690-D8EA1321-C2BB-41DF-AE6C-5B5A00422881Q28079075-05612C43-DCC6-4420-A4A1-CF9ADFD3FB28Q33572407-C4352747-9237-47FB-8529-1A5CE27403D7Q33640984-49A8EC5C-C9C1-4819-83FE-D66784C74489Q33720978-2D5B9122-910D-4245-A9B5-245D82909462Q33855053-BFE494D5-2075-4C33-B35C-328CCF5799BDQ34079306-0C95FF8C-92CE-4636-AE78-AD8801FDEC46Q34134870-A676C2E1-D9A2-434A-841F-27EC69AB9FD4Q34138308-BFDD1032-8A99-4109-A8A1-D156C0EAF36BQ34182764-799CFB96-C783-460F-971B-874D363337BCQ34483581-32119F4F-2237-4431-9C5A-F6571A10EC0FQ35070771-E3E0F194-5618-4705-8C08-7FE786A4884DQ35147597-7C57727A-D713-4495-A5B7-CDB016F07579Q35561695-D5F544DA-41DE-4DFC-B0B7-13F3DAD1AB47Q35888467-F4364202-736B-4576-81F6-E27F27DAD86BQ35949461-3070E854-B15F-495A-A00E-D3732FF1F4D8Q35981873-D0FDBC00-5FD9-4FB2-BD4A-B22FE3E96E1AQ35998435-AB09E938-BBB8-4B13-A6DF-F75162CBAA16Q36000232-8233F284-EBC7-47C1-843C-0A4070D60BD5Q36051517-5E5E6F78-F45A-4B9A-B89E-841348F83969Q36096641-6BC7D429-8FA0-4B40-A101-8EDA54E96301Q36230905-D7E8ED5A-17CC-404D-80BD-61AB3B8620C3Q36369415-A66F7417-EEA1-43A0-B65C-FEDD4128464EQ36396396-B890763E-FAD9-4A0C-9676-E1AB28D4744AQ37320122-8E818C1A-FB27-49ED-80B5-94C37D7CF9FFQ37604560-A3DC7329-5EC6-4794-8927-3E5D0ACE0484Q37698895-C7A104D0-9F49-4BDC-BBAD-C9654D70472AQ37723702-23579AD9-48CA-43C4-A620-C0998EAD590FQ37833066-8C8CBFA2-F146-4B40-BBBB-D70118ED1AC7Q37936584-38C84D5C-6190-4194-9DB2-E5563747082FQ37969851-F9DA8EBC-690D-430E-97C9-62E007A41F49Q38021921-65E0B658-31A1-4605-872D-E47EBBD281CBQ38059508-7D7659CA-FF4A-43F2-8885-EA22D8644679Q38061129-35E47E2E-83F4-464C-91D8-34D01B4B434AQ38118934-F9020886-84BF-44F3-B5DD-FA3D1CE35B31Q38172182-6ECC9F7D-EAEA-4F72-861B-754B2030306FQ38222512-276B1509-BDD4-4820-9E0F-F8A810C5CC45
P2860
Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Genetic modulation of the Let- ...... h salvage cetuximab-irinotecan
@ast
Genetic modulation of the Let- ...... h salvage cetuximab-irinotecan
@en
Genetic modulation of the Let- ...... h salvage cetuximab-irinotecan
@nl
type
label
Genetic modulation of the Let- ...... h salvage cetuximab-irinotecan
@ast
Genetic modulation of the Let- ...... h salvage cetuximab-irinotecan
@en
Genetic modulation of the Let- ...... h salvage cetuximab-irinotecan
@nl
prefLabel
Genetic modulation of the Let- ...... h salvage cetuximab-irinotecan
@ast
Genetic modulation of the Let- ...... h salvage cetuximab-irinotecan
@en
Genetic modulation of the Let- ...... h salvage cetuximab-irinotecan
@nl
P2093
P50
P921
P356
P1476
Genetic modulation of the Let- ...... h salvage cetuximab-irinotecan
@en
P2093
C Cremolini
E Canestrari
F Graziano
N Galluccio
P Giordani
S D'Emidio
V Catalano
P2888
P304
P356
10.1038/TPJ.2010.9
P407
P50
P577
2010-02-23T00:00:00Z
P6179
1028086336